Table 1 Demographics and baseline laboratory markers of training cohort and test cohort

Gender

Female

21 (33.3%)

6 (13.6%)

18 (43.9%)

13 (18.3%)

Male

42 (66.7%)

38 (86.4%)

22 (53.7%)

58 (81.7%)

Age

36.6 ± 13.8

52.4 ± 8.3

40.1 ± 11.9

51.1 ± 10.2

Serum HBV DNA

7.48

5.02

6.24

5.32

(log₁₀ IU/ml)

(6.50–7.83)

(4.43–6.25)

(4.89–7.65)

(4.80–5.85)

TBIL (μmol/L)

13

14.2

11

14.5

(10.0–17.0)

(11.1–19.8)

(8.7–15.7)

(11.5–19.4)

DBIL (μmol/L)

3

5.5

4

5.7

(3.0–5.0)

(4.0–7.7)

(3.0–6.0)

(4.4–7.5)

TP (g/L)

74

68.8

75

67.8

(71.5–79.0)

(64.4–71.1)

(70.0–78.0)

(64.1–72.7)

ALB (g/L)

45.5

39.8

45

40.9

(41.0–49.7)

(37.0–42.5)

(43.0–48.5)

(38.0–43.9)

ALT (U/L)

38

43.4

51

40.5

(19.0–66.0)

(24.7–78.4)

(29.5–77.0)

(33.0–71.0)

AST (U/L)

30

46

33

40

(21.0–45.0)

(25.0–84.5)

(26.5–54.2)

(31.0–64.0)

GGT (U/L)

22

81

24

78

(15.0–51.0)

(41.3–156.0)

(18.0–43.2)

(50.0–121.5)

ALP (U/L)

71.5

92

72

92

(59.299.7)

(69.25–131.5)

(56.0–82.5)

(73.5–112.0)

HBsAb

Negative

17 (40.5%)

36 (85.7%)

38 (97.4%)

64 (95.5%)

Postive

25 (59.5%)

6 (14.3%)

1 (2.6%)

3 (4.5%)

HBeAg

Negative

31 (73.8%)

25 (59.5%)

8 (20.5%)

41 (61.2%)

Postive

11 (26.2%)

17 (40.5%)

31 (79.5%)

26 (38.8%)

HBeAb

Negative

33 (78.6%)

10 (23.8%)

31 (79.5%)

18 (26.9%)

Postive

9 (21.4%)

32 (76.2%)

8 (20.5%)

49 (73.1%)

HBV genotype

B

26(41.2%)

8(17.4%)

15(36.6%)

12(16.9%)

C

37(58.7%)

36(78.3%)

26(63.4%)

59(83.1%)

Tumor size(cm)

5.6(3.32–9.40)

11(7.8–14.5)

Capsule

Intact

5 (11.4%)

10 (15.6%)

None

5 (11.4%)

11 (17.2%)

Partial

34 (77.3%)

43 (67.2%)

Tumor number

1

32 (72.7%)

58 (90.6%)

2

0 (0.0%)

3 (4.7%)

3

12 (27.3%)

3 (4.7%)

PVTT

None

23 (52.3%)

45(63.3%)

Yes

21 (47.7%)

19 (29.7%)

AFP(ng/ml)

565 (29.1–15,375.0)

187 (7.83–1210.0)